Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery.
• People whose cancer has a specific genetic change, falling into one of four groups: Group A (KIF5B/RET or related RET gene fusions), Group B (NTRK gene fusion, or MET or AXL gene overexpression, amplification, or mutation), Group C (ROS1 gene fusion), or Group D (RET gene fusion in people whose cancer continued to grow after treatment with a targeted RET-blocking drug).
• People who are 18 years of age or older at the time of signing the consent form.
• People whose cancer can be measured on scans using standard medical criteria (RECIST 1.1).
• People who are generally able to care for themselves and carry out normal activity, as measured by a standard medical performance scale (Karnofsky score above 70%).
• People whose blood cell counts, kidney function, liver function, and other blood test results fall within acceptable ranges as determined by the trial site (confirm specific values with trial site).
• People whose urine protein levels are within acceptable limits as determined by the trial site.
• People whose blood levels of phosphorus, magnesium, and potassium are at or above normal levels (with supplementation if needed).
• People who are willing and able to follow the study requirements and have signed the informed consent form.
• People who are sexually active and willing to use a barrier method of contraception (such as a condom) throughout the study and for 4 months after the last dose, along with a second form of birth control if they are capable of having children.
• Women who could potentially become pregnant must have a negative pregnancy test before starting the trial.

Who may not be able to join:

• People who have received any systemic cancer treatment (including experimental treatments) within 3 weeks before the first dose, or within 5 half-lives of that treatment, whichever is shorter (certain hormone-based therapies may be an exception — confirm with trial site).
• People who have previously been treated with cabozantinib (the study drug).
• People who have had radiation therapy to bone or brain within 2 weeks before the first dose, or any other external radiation or radioactive treatment within 4 weeks before the first dose, or who have ongoing complications from past radiation treatment.
• People who have not recovered from side effects of previous cancer treatments (except hair loss or other minor effects that are not medically significant).
• People who have uncontrolled brain metastases causing symptoms; however, people whose brain metastases have been treated and are stable on medication for more than 10 days, or who do not need such medication, may still be eligible (confirm with trial site).
• People who need to take blood-thinning medications at full treatment doses (such as warfarin, heparin, or antiplatelet drugs like clopidogrel), unless it would be unsafe to stop them; low-dose aspirin, very low-dose warfarin, and low molecular weight heparin are permitted.
• People who experienced significant vomiting of blood, gastrointestinal bleeding, coughing up blood, or other signs of bleeding in the lungs within 3 months before the first dose.
• People whose scans show hollow or cavity-like areas in the lungs caused by their tumour.
• People whose tumour is pressing against or growing into major blood vessels.
• People who have a tumour within the airways (windpipe or main bronchial tubes) within 28 days before the first dose.
• People with serious uncontrolled heart conditions, including moderate to severe heart failure, uncontrolled high blood pressure, a inherited condition called long QT syndrome, or who have had unstable chest pain, significant heart rhythm problems, stroke, heart attack, or a serious blood clot within 6 months before the first dose.
• People with serious bowel or stomach conditions that raise the risk of perforation or abnormal openings (fistulas), including active ulcers, inflammatory bowel disease, certain abdominal infections, or a history of bowel perforation or obstruction within 6 months before the first dose (confirm specific conditions with trial site).
• People who have had major surgery within 3 months before starting the trial, or minor surgery within 10 days, or who have not fully healed from any surgery.
• People with other conditions such as an active infection requiring treatment, a serious non-healing wound or fracture, a history of organ transplant, or uncontrolled thyroid problems within specified timeframes before the first dose (confirm with trial site).
• People who are unable to swallow tablets.
• People who have a specific type of abnormal heart rhythm reading (QTcF greater than 500 ms) on an ECG taken within 14 days before starting the trial.
• People who are pregnant or breastfeeding.
• People who have a known allergy or sensitivity to any ingredient in the study drug.
• People who are unwilling or unable to follow the study protocol or work with the research team.
• People who have another uncontrolled cancer that would make it difficult to assess how well the study drug is working.

Important: Always verify eligibility with the trial site directly before applying.